Loures Luciano Fernandes, Cândido Eduardo Batista, Vidigal Paula Vieira Teixeira, Seabra Mariana Ataydes Leite, Marco Luiz Armando Cunha de, Silva-Filho Agnaldo Lopes da
Department of Obstetrics and Gynecology, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Rev Bras Ginecol Obstet. 2014 May;36(5):205-10. doi: 10.1590/s0100-7203201400050004.
To investigate protein expression and mutations in phosphatase and tensin homolog (PTEN) in patients with stage IB cervical squamous cell carcinoma (CSCC) and the association with clinical-pathologic features, tumor p53 expression, cell proliferation and angiogenesis.
Women with stage IB CSCC (n=20 - Study Group) and uterine myoma (n=20 - Control Group), aged 49.1±1.7 years (mean±standard deviation, range 27-78 years), were prospectively evaluated. Patients with cervical cancer were submitted to Piver-Rutledge class III radical hysterectomy and pelvic lymphadenectomy and patients in the Control Group underwent vaginal hysterectomy. Tissue samples from the procedures were stained with hematoxylin and eosin for histological evaluation. Protein expression was detected by immunohistochemistry. Staining for PTEN, p53, Ki-67 and CD31 was evaluated. The intensity of PTEN immunostaining was estimated by computer-assisted image analysis, based on previously reported protocols. Data were analyzed using the Student's t-test to evaluate significant differences between the groups. Level of significance was set at p<0.05.
The PTEN expression intensity was lower in the CSCC group than in the Control (benign cervix) samples (150.5±5.2 versus 204.2±2.6; p<0.001). Our study did not identify any mutations after sequencing all nine PTEN exons. PTEN expression was not associated with tumor expression of p53 (p=0.9), CD31 (p=0.8) or Ki-67 (p=0.3) or clinical-pathologic features in patients with invasive carcinoma of the cervix.
Our findings demonstrate that the PTEN protein expression is significantly diminished in CSCC.
研究IB期宫颈鳞状细胞癌(CSCC)患者中磷酸酶和张力蛋白同源物(PTEN)的蛋白表达及突变情况,以及其与临床病理特征、肿瘤p53表达、细胞增殖和血管生成的关系。
对年龄为49.1±1.7岁(均值±标准差,范围27 - 78岁)的IB期CSCC患者(n = 20 - 研究组)和子宫肌瘤患者(n = 20 - 对照组)进行前瞻性评估。宫颈癌患者接受Piver-Rutledge III类根治性子宫切除术和盆腔淋巴结清扫术,对照组患者接受经阴道子宫切除术。手术获取的组织样本用苏木精和伊红染色进行组织学评估。通过免疫组织化学检测蛋白表达。评估PTEN、p53、Ki-67和CD31的染色情况。基于先前报道的方案,通过计算机辅助图像分析估计PTEN免疫染色的强度。使用学生t检验分析数据,以评估两组之间的显著差异。显著性水平设定为p<0.05。
CSCC组的PTEN表达强度低于对照组(良性宫颈)样本(150.5±5.2对204.2±2.6;p<0.001)。在对所有9个PTEN外显子进行测序后,我们的研究未发现任何突变。PTEN表达与宫颈癌患者的肿瘤p53表达(p = 0.9)、CD31表达(p = 0.8)或Ki-67表达(p = 0.3)以及临床病理特征均无关联。
我们的研究结果表明,CSCC中PTEN蛋白表达显著降低。